Outcomes of anti-PD-L1 blockades plus etoposide and platinum (EP) as first-line therapy for extensive-stage small-cell lung cancer (ES-SCLC) with brain metastasis (BM).

被引：0
|
作者：
Tian, Yaru
Ma, Ji
Zhu, Hui
Yu, Jinming
机构：
[1] Shandong First Med Univ & Shandong Acad Med Sci, Shandong Canc Hosp & Inst, Dept Radiat Oncol, Jinan, Peoples R China
[2] Peoples Hosp Leling, Dept Oncol, Leling, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e20607
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Outcomes of First-Line Anti-PD-L1 Blockades Combined with Brain Radiotherapy (BRT) for Extensive-Stage SmallCell Lung Cancer (ES-SCLC) with Brain Metastases (BM)
    Tian, Y.
    Ma, J.
    Zhu, H.
    Yu, J.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2022, 114 (03): : E360 - E360
  • [2] Outcomes of first-line anti-PD-L1 blockades combined with brain radiotherapy for extensive-stage small-cell lung cancer with brain metastasis
    Ji Ma
    Yaru Tian
    Shaoyu Hao
    Liangjie Zheng
    Weibo Hu
    Xiaoyang Zhai
    Dongfang Meng
    Hui Zhu
    Journal of Neuro-Oncology, 2022, 159 : 685 - 693
  • [3] Outcomes of first-line anti-PD-L1 blockades combined with brain radiotherapy for extensive-stage small-cell lung cancer with brain metastasis
    Ma, Ji
    Tian, Yaru
    Hao, Shaoyu
    Zheng, Liangjie
    Hu, Weibo
    Zhai, Xiaoyang
    Meng, Dongfang
    Zhu, Hui
    JOURNAL OF NEURO-ONCOLOGY, 2022, 159 (03) : 685 - 693
  • [4] KEYNOTE-604: Pembrolizumab (pembro) or placebo plus etoposide and platinum (EP) as first-line therapy for extensive-stage (ES) small-cell lung cancer (SCLC).
    Rudin, Charles M.
    Awad, Mark M.
    Navarro, Alejandro
    Gottfried, Maya
    Peters, Solange
    Csoszi, Tibor
    Cheema, Parneet Kaur
    Rodriguez-Abreu, Delvys
    Wollner, Mira
    Czyzewicz, Grzegorz
    Yang, James Chih-Hsin
    Mazieres, Julien
    Orlandi, Francisco J.
    Luft, Alexander
    Gumus, Mahmut
    Kato, Terufumi
    Kalemkerian, Gregory Peter
    Luo, Yiwen
    Pietanza, Maria Catherine
    Kim, Hye Ryun
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [5] KEYNOTE-604: Phase 3 trial of pembrolizumab plus etoposide/platinum (EP) for first-line treatment of extensive stage small-cell lung cancer (ES-SCLC)
    Rudin, C. M.
    Shen, L.
    Pietanza, M. C.
    ANNALS OF ONCOLOGY, 2017, 28
  • [6] Durvalumab (D) plus platinum-etoposide (EP) in 1L extensive-stage small-cell lung cancer (ES-SCLC): Exploratory analysis of SCLC molecular subtypes in CASPIAN
    Xie, Mingchao
    Chugh, Priti
    Broadhurst, Helen
    Lai, Zhongwu
    Whitston, David
    Paz-Ares, Luis
    Gay, Carl
    Byers, Lauren
    Rudin, Charles M.
    Stewart, Ross
    Barrett, J. Carl
    Shrestha, Yashaswi
    Panse, Jens
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 145 - 145
  • [7] Durvalumab (D) plus platinum-etoposide (EP) in 1L extensive-stage small-cell lung cancer (ES-SCLC): Exploratory analysis of SCLC molecular subtypes in CASPIAN
    Xie, Mingchao
    Chugh, Priti
    Broadhurst, Helen
    Lai, Zhongwu
    Whitston, David
    Paz-Ares, Luis
    Gay, Carl
    Byers, Lauren
    Rudin, Charles M.
    Stewart, Ross
    Barrett, J. Carl
    Shrestha, Yashaswi
    CANCER RESEARCH, 2022, 82 (12)
  • [8] Financial toxicity of front-line platinum etoposide plus atezolizumab versus durvalumab in extensive-stage small-cell (ES-SCLC) lung cancer.
    Harrison, Bradley
    Keith, Nicole
    Verbyla, Allison
    Mileham, Kathryn Finch
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (28) : 23 - 23
  • [9] Real-World Outcomes of Platinum-immunotherapy as First-Line (1L) Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
    Ganti, A. K.
    Prince, T.
    Back, S.
    Chansakul, A.
    Boccuti, A.
    Rengarajan, B.
    Chakrabarti, D.
    Li, W.
    Fan, L.
    Cao, Y.
    D'Agostino, R., Jr.
    Fan, X.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S664 - S665
  • [10] LUMINANCE: A Phase IIIb Study of Durvalumab plus Platinum-Etoposide for First-Line Treatment of Extensive-Stage SCLC (ES-SCLC)
    Reinmuth, N.
    DeMarinis, F.
    Leighl, N.
    Sadow, S.
    Davey, K.
    Ozguroglu, M.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S547 - S547
12345